Comparative assessment of the effects of short-term inhalation exposure to Nickel oxide nanoparticles and microdispersed Nickel oxide
- 25 Downloads
The biological effects of nickel oxide nanoparticles (Nickel (II) oxide, CAS number 1313-99-1, product number 637130) produced by Sigma-Aldrich (United States)) have been analyzed. The nanomaterial that was investigated consists of spherical particles with a hydrodynamic size of 17–40 nm; that is, the particle size is 9- to 38-fold less than the size of the particles of the microdispersed analog (150–1500 nm). CL50 of the samples investigated was higher than 5000 mg/m3 for BALB/C mice; therefore, the substances are classified as low-risk (class 4 hazardous substances). The capacity of nickel oxide nanoparticles used at the absolute concentration of 140194 ± 27768 particles/dm3 (equivalent to 1.34 ± 0.07 mg/dm3 nickel oxide) to accumulate in the lungs and blood after 4 h of inhalation exposure is higher than that of the microdispersed analog (39.27 times higher for accumulation in the lungs and 13.71 times higher for accumulation in blood); therefore, the nanoparticles are assumed to be more toxic than the microdispersed analog. This assumption is confirmed by the detection of morphological alterations that include the formation of focal perivascular and peribronchial lymphoid infiltrates with small amounts of macrophages and eosinophils in the lung tissue of BALB/C mice. The microdispersed analog applied at the same actual concentration does not induce the effect described above.
Unable to display preview. Download preview PDF.
- 1.W.-N. Wang, Y. Itoh, I. W. Lenggoro, and K. Okuyama, “Nickel and nickel oxide nanoparticles prepared from nickel nitrate hexahydrate by a low pressure spray pyrolysis,” Mater. Sci. Eng., 69–76 (2004).Google Scholar
- 3.J. M. Veranth, E. G. Kaser, M. M. Veranth, M. Koch, and G. S. Yost, “Cytokine responses of human lung cells (BEAS-2B) treated with micron-sized and nanoparticles of metal oxides compared to soil dusts,” Part Fibre Toxicol., 4–27 (2007).Google Scholar
- 6.“Nickel(II) oxide nanopowder, <50 nm particle size (TEM), 99.8% trace metals,” Material Safety Data Sheet (MSDS) (Sigma-Aldrich, 2014).Google Scholar
- 7.GOST (State Standard) No. 32646-2014, “Testing methods of chemicals effects on the human body. Acute inhalation toxicity - method for determining the class of acute toxicity” (OECD, Test No. 436:2008, IDT) (Standartinform, Moscow, 2015).Google Scholar
- 8.I. A. Minigalieva, L. I. Privalova, M. P. Sutunkova, B. A. Katsnelson, A. N. Varaksin, V. G. Panov, V. Ya. Shur, and E. V. Shishkina, “Pulmonary acute response to separate and combined deposition of manganese and nickel nanoparticles and its attenuation with a bio-protective pretreatment,” in Proceedings of the 2nd International Congress on Safety of Engineered Nanoparticles and Nanotechnologies SENN’2015, Helsinki, Finland, April 12–15, 2015.Google Scholar
- 9.N. V. Zaitseva, M. A. Zemlyanova, V. N. Zvezdin, O. V. Lebedinskaya, S. V. Melekhin, E. V. Saenko, and R. R. Makhmudov, “Toxicological evaluation of nanodispersed manganese oxide (III, IV) effect on morphological peculiarities of different tissues under experiment,” Vestn. Ross. Akad. Med. Nauk, No. 2, 18–23 (2013).CrossRefGoogle Scholar
- 10.N. V. Zaitseva, M. A. Zemlyanova, V. N. Zvezdin, T. I. Akaf’eva, D. L. Mazunina, and A. A. Dovbysh, “Effects of subchronic exposure manganese oxide nanoparticles on the central nervous system, lipid peroxidation and antioxidant enzymes in rats,” Analiz Riska Zdorov’yu, No. 4, 66–77 (2014).Google Scholar
- 11.El. Fröhlich, “Cellular targets and mechanisms in the cytotoxic action of non-biodegradable engineered nanoparticles,” Current Drug Metabolism, No. 9, 976–988 (2015).Google Scholar